MoonLake Immunotherapeutics
MLTX
$39.65
$0.982.53%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -230.31% | -76.82% | -18.21% | 5.62% | 27.95% |
| Total Depreciation and Amortization | 273.94% | 3,262.12% | 3,040.91% | 2,853.03% | 2,886.29% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 614.02% | 321.44% | 1,238.82% | 116.85% | 78.79% |
| Change in Net Operating Assets | 39.15% | -390.26% | -444.50% | -1,329.25% | -293.55% |
| Cash from Operations | -172.54% | -91.43% | -52.94% | 4.00% | 23.47% |
| Capital Expenditure | -82.57% | -- | -- | -- | -1,678.75% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -723.61% | 144.82% | -- | -477.00% | 22.97% |
| Cash from Investing | -716.36% | 144.35% | -- | -480.91% | 22.13% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -89.06% | -81.43% | -81.45% | 1,246,973.66% | 1,032,992.93% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 46.59% | -- | -- | -103.20% | -102.04% |
| Cash from Financing | -89.30% | -82.37% | -82.41% | 406.91% | 300.78% |
| Foreign Exchange rate Adjustments | 269.99% | -55.83% | 225.70% | -295.17% | -985.88% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -165.77% | -79.24% | -138.87% | 888.77% | 1,208.25% |
